Name | INNO-206 |
Synonyms | INNO-206 Aldoxorubicin Aldoxorubicin (INNO-206) Aldoxorubicin Aldoxorubicin DoxorubicinImpurity16Trifluoroacetate N-[(E)-[1-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-hydroxyethylidene]amino]-6-(2,5-dioxopyrrol-1-yl)hexanamide 1H-Pyrrole-1-hexanoic acid, 2,5-dihydro-2,5-dioxo-, (2E)-2-[1-[(2S,4S)-4-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl]-2-hydroxyethylidene]hydrazide (E)-N'-[1-[(2S,4S)-4-[[(2R,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-2-tetrahydropyranyl]oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-2-tetracenyl]-2-hydroxyethylidene]-6-(2,5-dioxo-2,5-dihydro-1-pyrrolyl)hexanehydrazide |
CAS | 1361644-26-9 |
Molecular Formula | C37H42N4O13 |
Molar Mass | 750.75 |
Density | 1.60±0.1 g/cm3(Predicted) |
pKa | 7.36±0.60(Predicted) |
Storage Condition | -20℃ |
In vitro study | Aldoxorubicin (INNO-206) (0.27 to 2.16 μM) inhibits blood vessel formation and reduces multiple myeloma cell growth in a pH-dependent fashion. |
In vivo study | Aldoxorubicin (INNO-206) (10.8 mg/kg, i.v.) shows significantly smaller tumor volumes and IgG levels on days 28, and is well tolerated with 90% of mice surviving until the termination of the study in the mice bearing the LAGκ-1A tumor. Aldoxorubicin (INNO-206) shows a good safety profile at doses up to 260 mg/mL doxorubicin equivalents, and is able to induce tumor regressions in breast cancer, small cell lung cancer and sarcoma in phase I study. Aldoxorubicin (INNO-206) shows superior activity over doxorubicin in a murine renal cell carcinoma model and in breast carcinoma xenograft models. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.332 ml | 6.66 ml | 13.32 ml |
5 mM | 0.266 ml | 1.332 ml | 2.664 ml |
10 mM | 0.133 ml | 0.666 ml | 1.332 ml |
5 mM | 0.027 ml | 0.133 ml | 0.266 ml |